ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma

ARID1A, a member of the chromatin remodeling SWI/SNF complex, is frequently lost in many cancer types, including esophageal adenocarcinoma (EAC). Here, we study the impact of ARID1A deficiency on the anti-tumor immune response in EAC. We find that EAC tumors with ARID1A mutations are associated with...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Le Zhang [verfasserIn] Yueyuan Zheng [verfasserIn] Wenwen Chien [verfasserIn] Benjamin Ziman [verfasserIn] Sandrine Billet [verfasserIn] H. Phillip Koeffler [verfasserIn] De-Chen Lin [verfasserIn] Neil A. Bhowmick [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Schlagwörter:	ARID1A esophageal adenocarcinoma CD8 IFN response tumor immunity lipid metabolism

Übergeordnetes Werk:	In: Cancers - MDPI AG, 2010, 15(2023), 22, p 5377
Übergeordnetes Werk:	volume:15 ; year:2023 ; number:22, p 5377

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/cancers15225377

Katalog-ID:	DOAJ101263716

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ101263716
003	DE-627
005	20240414153110.0
007	cr uuu---uuuuu
008	240414s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/cancers15225377 \|2 doi
035			\|a (DE-627)DOAJ101263716
035			\|a (DE-599)DOAJ528d9206b84940d583e41306da8ecfcd
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
100	0		\|a Le Zhang \|e verfasserin \|4 aut
245	1	0	\|a ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a ARID1A, a member of the chromatin remodeling SWI/SNF complex, is frequently lost in many cancer types, including esophageal adenocarcinoma (EAC). Here, we study the impact of ARID1A deficiency on the anti-tumor immune response in EAC. We find that EAC tumors with ARID1A mutations are associated with enhanced tumor-infiltrating CD8<sup<+</sup< T cell levels. ARID1A-deficient EAC cells exhibit heightened IFN response signaling and promote CD8<sup<+</sup< T cell recruitment and cytolytic activity. Moreover, we demonstrate that ARID1A regulates fatty acid metabolism genes in EAC, showing that fatty acid metabolism could also regulate CD8<sup<+</sup< T cell recruitment and CD8<sup<+</sup< T cell cytolytic activity in EAC cells. These results suggest that ARID1A deficiency shapes both tumor immunity and lipid metabolism in EAC, with significant implications for immune checkpoint blockade therapy in EAC.
650		4	\|a ARID1A
650		4	\|a esophageal adenocarcinoma
650		4	\|a CD8<sup<+</sup< T cells
650		4	\|a IFN response
650		4	\|a tumor immunity
650		4	\|a lipid metabolism
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Yueyuan Zheng \|e verfasserin \|4 aut
700	0		\|a Wenwen Chien \|e verfasserin \|4 aut
700	0		\|a Benjamin Ziman \|e verfasserin \|4 aut
700	0		\|a Sandrine Billet \|e verfasserin \|4 aut
700	0		\|a H. Phillip Koeffler \|e verfasserin \|4 aut
700	0		\|a De-Chen Lin \|e verfasserin \|4 aut
700	0		\|a Neil A. Bhowmick \|e verfasserin \|4 aut
773	0	8	\|i In \|t Cancers \|d MDPI AG, 2010 \|g 15(2023), 22, p 5377 \|w (DE-627)614095670 \|w (DE-600)2527080-1 \|x 20726694 \|7 nnns
773	1	8	\|g volume:15 \|g year:2023 \|g number:22, p 5377
856	4	0	\|u https://doi.org/10.3390/cancers15225377 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/528d9206b84940d583e41306da8ecfcd \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/2072-6694/15/22/5377 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2072-6694 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 15 \|j 2023 \|e 22, p 5377

Indexfelder

author_variant	l z lz y z yz w c wc b z bz s b sb h p k hpk d c l dcl n a b nab
matchkey_str	article:20726694:2023----::rdaeiinyeuaeattmrmueepnensp
hierarchy_sort_str	2023
callnumber-subject-code	RC
publishDate	2023
allfields	10.3390/cancers15225377 doi (DE-627)DOAJ101263716 (DE-599)DOAJ528d9206b84940d583e41306da8ecfcd DE-627 ger DE-627 rakwb eng RC254-282 Le Zhang verfasserin aut ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ARID1A, a member of the chromatin remodeling SWI/SNF complex, is frequently lost in many cancer types, including esophageal adenocarcinoma (EAC). Here, we study the impact of ARID1A deficiency on the anti-tumor immune response in EAC. We find that EAC tumors with ARID1A mutations are associated with enhanced tumor-infiltrating CD8<sup<+</sup< T cell levels. ARID1A-deficient EAC cells exhibit heightened IFN response signaling and promote CD8<sup<+</sup< T cell recruitment and cytolytic activity. Moreover, we demonstrate that ARID1A regulates fatty acid metabolism genes in EAC, showing that fatty acid metabolism could also regulate CD8<sup<+</sup< T cell recruitment and CD8<sup<+</sup< T cell cytolytic activity in EAC cells. These results suggest that ARID1A deficiency shapes both tumor immunity and lipid metabolism in EAC, with significant implications for immune checkpoint blockade therapy in EAC. ARID1A esophageal adenocarcinoma CD8<sup<+</sup< T cells IFN response tumor immunity lipid metabolism Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yueyuan Zheng verfasserin aut Wenwen Chien verfasserin aut Benjamin Ziman verfasserin aut Sandrine Billet verfasserin aut H. Phillip Koeffler verfasserin aut De-Chen Lin verfasserin aut Neil A. Bhowmick verfasserin aut In Cancers MDPI AG, 2010 15(2023), 22, p 5377 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:15 year:2023 number:22, p 5377 https://doi.org/10.3390/cancers15225377 kostenfrei https://doaj.org/article/528d9206b84940d583e41306da8ecfcd kostenfrei https://www.mdpi.com/2072-6694/15/22/5377 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2023 22, p 5377
spelling	10.3390/cancers15225377 doi (DE-627)DOAJ101263716 (DE-599)DOAJ528d9206b84940d583e41306da8ecfcd DE-627 ger DE-627 rakwb eng RC254-282 Le Zhang verfasserin aut ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ARID1A, a member of the chromatin remodeling SWI/SNF complex, is frequently lost in many cancer types, including esophageal adenocarcinoma (EAC). Here, we study the impact of ARID1A deficiency on the anti-tumor immune response in EAC. We find that EAC tumors with ARID1A mutations are associated with enhanced tumor-infiltrating CD8<sup<+</sup< T cell levels. ARID1A-deficient EAC cells exhibit heightened IFN response signaling and promote CD8<sup<+</sup< T cell recruitment and cytolytic activity. Moreover, we demonstrate that ARID1A regulates fatty acid metabolism genes in EAC, showing that fatty acid metabolism could also regulate CD8<sup<+</sup< T cell recruitment and CD8<sup<+</sup< T cell cytolytic activity in EAC cells. These results suggest that ARID1A deficiency shapes both tumor immunity and lipid metabolism in EAC, with significant implications for immune checkpoint blockade therapy in EAC. ARID1A esophageal adenocarcinoma CD8<sup<+</sup< T cells IFN response tumor immunity lipid metabolism Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yueyuan Zheng verfasserin aut Wenwen Chien verfasserin aut Benjamin Ziman verfasserin aut Sandrine Billet verfasserin aut H. Phillip Koeffler verfasserin aut De-Chen Lin verfasserin aut Neil A. Bhowmick verfasserin aut In Cancers MDPI AG, 2010 15(2023), 22, p 5377 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:15 year:2023 number:22, p 5377 https://doi.org/10.3390/cancers15225377 kostenfrei https://doaj.org/article/528d9206b84940d583e41306da8ecfcd kostenfrei https://www.mdpi.com/2072-6694/15/22/5377 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2023 22, p 5377
allfields_unstemmed	10.3390/cancers15225377 doi (DE-627)DOAJ101263716 (DE-599)DOAJ528d9206b84940d583e41306da8ecfcd DE-627 ger DE-627 rakwb eng RC254-282 Le Zhang verfasserin aut ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ARID1A, a member of the chromatin remodeling SWI/SNF complex, is frequently lost in many cancer types, including esophageal adenocarcinoma (EAC). Here, we study the impact of ARID1A deficiency on the anti-tumor immune response in EAC. We find that EAC tumors with ARID1A mutations are associated with enhanced tumor-infiltrating CD8<sup<+</sup< T cell levels. ARID1A-deficient EAC cells exhibit heightened IFN response signaling and promote CD8<sup<+</sup< T cell recruitment and cytolytic activity. Moreover, we demonstrate that ARID1A regulates fatty acid metabolism genes in EAC, showing that fatty acid metabolism could also regulate CD8<sup<+</sup< T cell recruitment and CD8<sup<+</sup< T cell cytolytic activity in EAC cells. These results suggest that ARID1A deficiency shapes both tumor immunity and lipid metabolism in EAC, with significant implications for immune checkpoint blockade therapy in EAC. ARID1A esophageal adenocarcinoma CD8<sup<+</sup< T cells IFN response tumor immunity lipid metabolism Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yueyuan Zheng verfasserin aut Wenwen Chien verfasserin aut Benjamin Ziman verfasserin aut Sandrine Billet verfasserin aut H. Phillip Koeffler verfasserin aut De-Chen Lin verfasserin aut Neil A. Bhowmick verfasserin aut In Cancers MDPI AG, 2010 15(2023), 22, p 5377 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:15 year:2023 number:22, p 5377 https://doi.org/10.3390/cancers15225377 kostenfrei https://doaj.org/article/528d9206b84940d583e41306da8ecfcd kostenfrei https://www.mdpi.com/2072-6694/15/22/5377 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2023 22, p 5377
allfieldsGer	10.3390/cancers15225377 doi (DE-627)DOAJ101263716 (DE-599)DOAJ528d9206b84940d583e41306da8ecfcd DE-627 ger DE-627 rakwb eng RC254-282 Le Zhang verfasserin aut ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ARID1A, a member of the chromatin remodeling SWI/SNF complex, is frequently lost in many cancer types, including esophageal adenocarcinoma (EAC). Here, we study the impact of ARID1A deficiency on the anti-tumor immune response in EAC. We find that EAC tumors with ARID1A mutations are associated with enhanced tumor-infiltrating CD8<sup<+</sup< T cell levels. ARID1A-deficient EAC cells exhibit heightened IFN response signaling and promote CD8<sup<+</sup< T cell recruitment and cytolytic activity. Moreover, we demonstrate that ARID1A regulates fatty acid metabolism genes in EAC, showing that fatty acid metabolism could also regulate CD8<sup<+</sup< T cell recruitment and CD8<sup<+</sup< T cell cytolytic activity in EAC cells. These results suggest that ARID1A deficiency shapes both tumor immunity and lipid metabolism in EAC, with significant implications for immune checkpoint blockade therapy in EAC. ARID1A esophageal adenocarcinoma CD8<sup<+</sup< T cells IFN response tumor immunity lipid metabolism Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yueyuan Zheng verfasserin aut Wenwen Chien verfasserin aut Benjamin Ziman verfasserin aut Sandrine Billet verfasserin aut H. Phillip Koeffler verfasserin aut De-Chen Lin verfasserin aut Neil A. Bhowmick verfasserin aut In Cancers MDPI AG, 2010 15(2023), 22, p 5377 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:15 year:2023 number:22, p 5377 https://doi.org/10.3390/cancers15225377 kostenfrei https://doaj.org/article/528d9206b84940d583e41306da8ecfcd kostenfrei https://www.mdpi.com/2072-6694/15/22/5377 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2023 22, p 5377
allfieldsSound	10.3390/cancers15225377 doi (DE-627)DOAJ101263716 (DE-599)DOAJ528d9206b84940d583e41306da8ecfcd DE-627 ger DE-627 rakwb eng RC254-282 Le Zhang verfasserin aut ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier ARID1A, a member of the chromatin remodeling SWI/SNF complex, is frequently lost in many cancer types, including esophageal adenocarcinoma (EAC). Here, we study the impact of ARID1A deficiency on the anti-tumor immune response in EAC. We find that EAC tumors with ARID1A mutations are associated with enhanced tumor-infiltrating CD8<sup<+</sup< T cell levels. ARID1A-deficient EAC cells exhibit heightened IFN response signaling and promote CD8<sup<+</sup< T cell recruitment and cytolytic activity. Moreover, we demonstrate that ARID1A regulates fatty acid metabolism genes in EAC, showing that fatty acid metabolism could also regulate CD8<sup<+</sup< T cell recruitment and CD8<sup<+</sup< T cell cytolytic activity in EAC cells. These results suggest that ARID1A deficiency shapes both tumor immunity and lipid metabolism in EAC, with significant implications for immune checkpoint blockade therapy in EAC. ARID1A esophageal adenocarcinoma CD8<sup<+</sup< T cells IFN response tumor immunity lipid metabolism Neoplasms. Tumors. Oncology. Including cancer and carcinogens Yueyuan Zheng verfasserin aut Wenwen Chien verfasserin aut Benjamin Ziman verfasserin aut Sandrine Billet verfasserin aut H. Phillip Koeffler verfasserin aut De-Chen Lin verfasserin aut Neil A. Bhowmick verfasserin aut In Cancers MDPI AG, 2010 15(2023), 22, p 5377 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:15 year:2023 number:22, p 5377 https://doi.org/10.3390/cancers15225377 kostenfrei https://doaj.org/article/528d9206b84940d583e41306da8ecfcd kostenfrei https://www.mdpi.com/2072-6694/15/22/5377 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2023 22, p 5377
language	English
source	In Cancers 15(2023), 22, p 5377 volume:15 year:2023 number:22, p 5377
sourceStr	In Cancers 15(2023), 22, p 5377 volume:15 year:2023 number:22, p 5377
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	ARID1A esophageal adenocarcinoma CD8<sup<+</sup< T cells IFN response tumor immunity lipid metabolism Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Cancers
authorswithroles_txt_mv	Le Zhang @@aut@@ Yueyuan Zheng @@aut@@ Wenwen Chien @@aut@@ Benjamin Ziman @@aut@@ Sandrine Billet @@aut@@ H. Phillip Koeffler @@aut@@ De-Chen Lin @@aut@@ Neil A. Bhowmick @@aut@@
publishDateDaySort_date	2023-01-01T00:00:00Z
hierarchy_top_id	614095670
id	DOAJ101263716
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ101263716</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414153110.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers15225377</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ101263716</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ528d9206b84940d583e41306da8ecfcd</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Le Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">ARID1A, a member of the chromatin remodeling SWI/SNF complex, is frequently lost in many cancer types, including esophageal adenocarcinoma (EAC). Here, we study the impact of ARID1A deficiency on the anti-tumor immune response in EAC. We find that EAC tumors with ARID1A mutations are associated with enhanced tumor-infiltrating CD8<sup<+</sup< T cell levels. ARID1A-deficient EAC cells exhibit heightened IFN response signaling and promote CD8<sup<+</sup< T cell recruitment and cytolytic activity. Moreover, we demonstrate that ARID1A regulates fatty acid metabolism genes in EAC, showing that fatty acid metabolism could also regulate CD8<sup<+</sup< T cell recruitment and CD8<sup<+</sup< T cell cytolytic activity in EAC cells. These results suggest that ARID1A deficiency shapes both tumor immunity and lipid metabolism in EAC, with significant implications for immune checkpoint blockade therapy in EAC.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ARID1A</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">esophageal adenocarcinoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CD8<sup<+</sup< T cells</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IFN response</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">tumor immunity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lipid metabolism</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yueyuan Zheng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wenwen Chien</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Benjamin Ziman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sandrine Billet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">H. Phillip Koeffler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">De-Chen Lin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Neil A. Bhowmick</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">15(2023), 22, p 5377</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:22, p 5377</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers15225377</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/528d9206b84940d583e41306da8ecfcd</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/15/22/5377</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2023</subfield><subfield code="e">22, p 5377</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Le Zhang
spellingShingle	Le Zhang misc RC254-282 misc ARID1A misc esophageal adenocarcinoma misc CD8<sup<+</sup< T cells misc IFN response misc tumor immunity misc lipid metabolism misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma
authorStr	Le Zhang
ppnlink_with_tag_str_mv	@@773@@(DE-627)614095670
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	20726694
topic_title	RC254-282 ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma ARID1A esophageal adenocarcinoma CD8<sup<+</sup< T cells IFN response tumor immunity lipid metabolism
topic	misc RC254-282 misc ARID1A misc esophageal adenocarcinoma misc CD8<sup<+</sup< T cells misc IFN response misc tumor immunity misc lipid metabolism misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc ARID1A misc esophageal adenocarcinoma misc CD8<sup<+</sup< T cells misc IFN response misc tumor immunity misc lipid metabolism misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc ARID1A misc esophageal adenocarcinoma misc CD8<sup<+</sup< T cells misc IFN response misc tumor immunity misc lipid metabolism misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Cancers
hierarchy_parent_id	614095670
hierarchy_top_title	Cancers
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)614095670 (DE-600)2527080-1
title	ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma
ctrlnum	(DE-627)DOAJ101263716 (DE-599)DOAJ528d9206b84940d583e41306da8ecfcd
title_full	ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma
author_sort	Le Zhang
journal	Cancers
journalStr	Cancers
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2023
contenttype_str_mv	txt
author_browse	Le Zhang Yueyuan Zheng Wenwen Chien Benjamin Ziman Sandrine Billet H. Phillip Koeffler De-Chen Lin Neil A. Bhowmick
container_volume	15
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Le Zhang
doi_str_mv	10.3390/cancers15225377
author2-role	verfasserin
title_sort	arid1a deficiency regulates anti-tumor immune response in esophageal adenocarcinoma
callnumber	RC254-282
title_auth	ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma
abstract	ARID1A, a member of the chromatin remodeling SWI/SNF complex, is frequently lost in many cancer types, including esophageal adenocarcinoma (EAC). Here, we study the impact of ARID1A deficiency on the anti-tumor immune response in EAC. We find that EAC tumors with ARID1A mutations are associated with enhanced tumor-infiltrating CD8<sup<+</sup< T cell levels. ARID1A-deficient EAC cells exhibit heightened IFN response signaling and promote CD8<sup<+</sup< T cell recruitment and cytolytic activity. Moreover, we demonstrate that ARID1A regulates fatty acid metabolism genes in EAC, showing that fatty acid metabolism could also regulate CD8<sup<+</sup< T cell recruitment and CD8<sup<+</sup< T cell cytolytic activity in EAC cells. These results suggest that ARID1A deficiency shapes both tumor immunity and lipid metabolism in EAC, with significant implications for immune checkpoint blockade therapy in EAC.
abstractGer	ARID1A, a member of the chromatin remodeling SWI/SNF complex, is frequently lost in many cancer types, including esophageal adenocarcinoma (EAC). Here, we study the impact of ARID1A deficiency on the anti-tumor immune response in EAC. We find that EAC tumors with ARID1A mutations are associated with enhanced tumor-infiltrating CD8<sup<+</sup< T cell levels. ARID1A-deficient EAC cells exhibit heightened IFN response signaling and promote CD8<sup<+</sup< T cell recruitment and cytolytic activity. Moreover, we demonstrate that ARID1A regulates fatty acid metabolism genes in EAC, showing that fatty acid metabolism could also regulate CD8<sup<+</sup< T cell recruitment and CD8<sup<+</sup< T cell cytolytic activity in EAC cells. These results suggest that ARID1A deficiency shapes both tumor immunity and lipid metabolism in EAC, with significant implications for immune checkpoint blockade therapy in EAC.
abstract_unstemmed	ARID1A, a member of the chromatin remodeling SWI/SNF complex, is frequently lost in many cancer types, including esophageal adenocarcinoma (EAC). Here, we study the impact of ARID1A deficiency on the anti-tumor immune response in EAC. We find that EAC tumors with ARID1A mutations are associated with enhanced tumor-infiltrating CD8<sup<+</sup< T cell levels. ARID1A-deficient EAC cells exhibit heightened IFN response signaling and promote CD8<sup<+</sup< T cell recruitment and cytolytic activity. Moreover, we demonstrate that ARID1A regulates fatty acid metabolism genes in EAC, showing that fatty acid metabolism could also regulate CD8<sup<+</sup< T cell recruitment and CD8<sup<+</sup< T cell cytolytic activity in EAC cells. These results suggest that ARID1A deficiency shapes both tumor immunity and lipid metabolism in EAC, with significant implications for immune checkpoint blockade therapy in EAC.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	22, p 5377
title_short	ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma
url	https://doi.org/10.3390/cancers15225377 https://doaj.org/article/528d9206b84940d583e41306da8ecfcd https://www.mdpi.com/2072-6694/15/22/5377 https://doaj.org/toc/2072-6694
remote_bool	true
author2	Yueyuan Zheng Wenwen Chien Benjamin Ziman Sandrine Billet H. Phillip Koeffler De-Chen Lin Neil A. Bhowmick
author2Str	Yueyuan Zheng Wenwen Chien Benjamin Ziman Sandrine Billet H. Phillip Koeffler De-Chen Lin Neil A. Bhowmick
ppnlink	614095670
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/cancers15225377
callnumber-a	RC254-282
up_date	2024-07-03T19:39:12.065Z
_version_	1803587999044206592
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ101263716</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414153110.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers15225377</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ101263716</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ528d9206b84940d583e41306da8ecfcd</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Le Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">ARID1A, a member of the chromatin remodeling SWI/SNF complex, is frequently lost in many cancer types, including esophageal adenocarcinoma (EAC). Here, we study the impact of ARID1A deficiency on the anti-tumor immune response in EAC. We find that EAC tumors with ARID1A mutations are associated with enhanced tumor-infiltrating CD8<sup<+</sup< T cell levels. ARID1A-deficient EAC cells exhibit heightened IFN response signaling and promote CD8<sup<+</sup< T cell recruitment and cytolytic activity. Moreover, we demonstrate that ARID1A regulates fatty acid metabolism genes in EAC, showing that fatty acid metabolism could also regulate CD8<sup<+</sup< T cell recruitment and CD8<sup<+</sup< T cell cytolytic activity in EAC cells. These results suggest that ARID1A deficiency shapes both tumor immunity and lipid metabolism in EAC, with significant implications for immune checkpoint blockade therapy in EAC.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ARID1A</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">esophageal adenocarcinoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CD8<sup<+</sup< T cells</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IFN response</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">tumor immunity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lipid metabolism</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yueyuan Zheng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wenwen Chien</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Benjamin Ziman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sandrine Billet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">H. Phillip Koeffler</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">De-Chen Lin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Neil A. Bhowmick</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">15(2023), 22, p 5377</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:22, p 5377</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers15225377</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/528d9206b84940d583e41306da8ecfcd</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/15/22/5377</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2023</subfield><subfield code="e">22, p 5377</subfield></datafield></record></collection>
score	7.402733

Nicht das Richtige dabei?

Schreiben Sie uns!

ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?